Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inspire Pharmaceuticals, Inc.

http://www.inspirepharm.com

Latest From Inspire Pharmaceuticals, Inc.

Tech Transfer: BMS, Evotec Partner With Four UK Universities On Translational Research Efforts

The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.

Tech Transfer Deals Deals

Three IPOs, Three SPAC Mergers, But One Company Opted Out

Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.

Financing Business Strategies

Finance Watch: Roivant To Go Public In SPAC Merger, Raise $611m

Public Company Edition: Roivant’s deal sets its market cap at $7.3bn. Beyond the Werewolf and Vaccitech offerings, more drug developers are slated to go public during the first week of May. And in follow-on offerings, COMPASS Pathways raises $144m and Aldeyra brings in $125m.

Finance Watch Deals

BridgeBio's Calcilytix Sees POC For Encaleret And Options To Discuss With FDA

Calcilytix chief medical officer Jonathan Fox talked to Scrip about the development plans for encaleret for the rare form of hypoparathyroidism.

Research & Development Research and Development Strategies
See All

Company Information

UsernamePublicRestriction

Register